Dr. Sanjay K Banerjee is an experimental biologist and molecular pharmacologist. His research interest is to understand the molecular mechanism of metabolic disease and identify novel targets for therapeutic intervention. Sanjay obtained his Bachelor and Master of Pharmacy from Jadavpur University, Kolkata. He was awarded PhD in Pharmacology from All India Institute of Medical Sciences (AIIMS), New Delhi, India where he studied the pathological changes in ischemia-reperfusion injury in heart and evaluated the efficacy of various pharmacological agents. Sanjay then joined the Department of Medicine, SUNY Upstate Medical University as a post-doctoral fellow, to identify mutations in the transaldolase (TAL) gene in patients with Systemic Lupus Erythrometosus (SLE). He also worked with TAL knockout mice. In 2005, he moved to the Cardiovascular Institute, University of Pittsburgh, where he trained to generate transgenic and gene-targeted mouse models with human mutations, and elucidated the role of mutant genes in cardiac failure.
He has generated PRKAG2 mutant mouse with glycogen storage cardiomyopathy as well as cardiac hypertrophy. His research work uncovered the mechanism of glycogen storage in heart, and revealed a novel and third cardiac glucose transporter, sodium dependent glucose transporter 1 (SGLT1). He characterized the glucose transporter, SGLT1 and identified it as a novel target for glycogen storage cardiomyopathy. In 2009 he received the prestigious Ramalingaswami Fellowship from the Department of Biotechnology and joined at the Department of Medicinal Chemistry and Pharmacology, CSIR-Indian Institute of Chemical Technology, Hyderabad where he developed animal models of hypertrophic and diabetic cardiomyopathy. His study found that activation of sirtuins attenuate cardiac defects and reverse the cardiac complication. Several GATA4 and NKX2.5 gene mutations were identified from congenital heart disease patients from South India. He has also developed assay systems to screen small molecules against cardiovascular disease and diabetes. In 2014, he joined the DDRC where he continues with his interests to understand molecular mechanisms and identify novel targets for diabetes and cardiovascular disease.